OmniAb SPAC Presentation Deck

COMPETITIVE BENCHMARKING THREE CLEAR LEADERS IN INTEGRATED ANTIBODY DISCOVERY Active Partners Active Programs Approved Registration Phase 3 Phase 2 Phase 1 Antigen Generation Species Diversity Screening Capabilities Identification Programs by Stage Technologies Capabilities OmniAb 56(1) 252(1) 2 1 2 NN 2 18 ✓✓✓ ✓✓✓ ✓✓✓ ✓✓✓ √✓ ✓ AbCellera 36(2,3) 78(2,3) 1 1 3 ✓ ✓✓✓ ✓✓✓ ✓✓✓ ✓ ✓ ADIMAB 95(3) 425(3) 1 55(3) x ✓ ✓ ✓ ✓ Analyze Engineer Sources: AbCellera Corporate Presentations dated 11/9/21 and 2/24/22; Adimab "Update on 2021 Partnership Activities" press release dated 1/12/22; Technologies capabilities based on Ligand's internal assessment. (1) Includes 56 active partners and 248 active programs with downstream economics. (2) Includes 26 active partners and 54 active programs with downstream economics. (3) AbCellera and Adimab do not disclose if programs or partnerships are ongoing or terminated. ✓✓ ✓✓✓ 25 OmniAb

View entire presentation